Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Penwest Pharmaceuticals (NasdaqNM:PPCO)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Recent Events
July 24Price hit new 52-week high ($21.00)
Location
2981 Route 22
Patterson, NY 12563
Phone: (845) 878-3414
Fax: (845) 878-3484
Email: investor@penw.com
Employees (last reported count): 137
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 10%
·Over the last 6 months:
 · one insider sell; 7,000  shares
  (0.5% of insider shares)
·Institutional: 23% (25% of float)
(67 institutions)
·Net Inst. Selling: 189.0K shares (+5.81%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Penwest Pharmaceuticals Co. is engaged in the research, development and commercialization of novel drug delivery technologies and has expertise in developing, manufacturing and selling excipient ingredients for the pharmaceutical industry. Based on its fundamental expertise in tabletting ingredients, the Company has developed its proprietary Timerx controlled-release drug delivery technology, which is applicable to a broad range of orally administered drugs, and ProSolv, a co-processing drug delivery technology platform. The Company is utilizing the Timerx system to formulate generic versions of branded controlled-release drugs, controlled-release formulations of marketed immediate-release drugs and New Chemical Entities. The Company is also engaged in the development, production and distribution of branded pharmaceutical excipients, which are the inactive components included in tablets and capsules.
More from Market Guide: Expanded Business Description

Financial Summary
Penwest Pharmaceuticals Co. is engaged in the research, development and commercialization of novel drug delivery technologies. The Company also manufactures and distributes excipients. For the six months ended 6/30/01, revenues rose 1% to $20.5 million. Net loss before acct. change rose 55% to $5.3 million. Revenues reflect higher royalties earned on Mylan's sales of the 30 mg strength of generic Procadia XL. Higher loss reflects increased professional fees.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Tod Hamachek, 55
Chairman of Directors and CEO
$406K--  
Jennifer Good, 36
CFO, VP-Fin.
196K--  
Anand Baichwal, Ph.D, 46
Sr. VP of R&D
225K--  
Stephen Berte, Jr., 45
Gen. Mang., Excipients Bus.
182K$29K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:PPCOAs of 31-Aug-2001
Price and Volume
52-Week Low
on 30-Nov-2000
$7.625
Recent Price$18.29 
52-Week High
on 24-July-2001
$21.00 
Beta0.20 
Daily Volume (3-month avg)144.6K
Daily Volume (10-day avg)80.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change+47.0%
52-Week Change
relative to S&P500
+97.3%
Share-Related Items
Market Capitalization$278.4M
Shares Outstanding15.2M
Float13.7M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.02 
Earnings (ttm)-$0.81 
Earnings (mrq)-$0.25 
Sales (ttm)$3.34 
Cash (mrq)$0.09 
Valuation Ratios
Price/Book (mrq)9.07 
Price/EarningsN/A 
Price/Sales (ttm)5.47 
Income Statements
Sales (ttm)$42.3M
EBITDA (ttm)-$9.84M
Income available to common (ttm)-$10.2M
Profitability
Profit Margin (ttm)-24.1%
Operating Margin (ttm)-23.2%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-24.02%
Return on Equity (ttm)-32.86%
Financial Strength
Current Ratio (mrq)1.74 
Debt/Equity (mrq)0.11 
Total Cash (mrq)$1.15M
Short Interest
As of 8-Aug-2001
Shares Short628.0K
Percent of Float4.6%
Shares Short
(Prior Month)
589.0K
Short Ratio3.49 
Daily Volume180.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.